Literature DB >> 24080775

HCV transmission in industrialized countries and resource-constrained areas.

Mark Thursz1, Arnaud Fontanet2.   

Abstract

HCV is a blood-borne virus transmitted by percutaneous exposure to infected blood or blood-derived body fluids. The main routes of transmission are blood transfusions, medical procedures and injection drug use. In industrialized countries, HCV transmission through blood transfusions has been virtually eliminated and iatrogenic transmission occurs only sporadically during local breaches of infection control procedures. As most new cases originate from injection drug use, harm-reduction programmes (including opiate substitution, needle exchange and health education) can greatly reduce HCV transmission. Currently, the main approach to reduce the HCV disease burden is by increasing awareness of both the public and health-care providers to hepatitis C, enhancing screening opportunities and treatment of the infected population. In resource-limited countries, the priority is reducing transmission through blood transfusions and invasive medical procedures. This approach requires training of health-care providers and also structural changes and financial investments in countries where antibody screening, disposable materials and effective sterilization procedures are not routinely available. In these countries, reducing the HCV burden has been hampered by limited access to treatment, largely owing to the cost of drugs. Access to treatment is moving up on the agenda of international and non-governmental organizations in conjunction with the future availability of highly efficacious oral drug regimens.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24080775     DOI: 10.1038/nrgastro.2013.179

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  34 in total

Review 1.  Current and Future Burden of Chronic Nonmalignant Liver Disease.

Authors:  Prowpanga Udompap; Donghee Kim; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

Review 2.  CROI 2016: Viral Hepatitis and Liver Fibrosis.

Authors:  Anne F Luetkemeyer; David L Wyles
Journal:  Top Antivir Med       Date:  2016 May-Jun

Review 3.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

4.  Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.

Authors:  Leopold Kong; David E Lee; Rameshwar U Kadam; Tong Liu; Erick Giang; Travis Nieusma; Fernando Garces; Netanel Tzarum; Virgil L Woods; Andrew B Ward; Sheng Li; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

Review 5.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

6.  A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.

Authors:  Jason Gummow; Yanrui Li; Wenbo Yu; Tamsin Garrod; Danushka Wijesundara; Amelia J Brennan; Ranajoy Mullick; Ilia Voskoboinik; Branka Grubor-Bauk; Eric J Gowans
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

Review 7.  Hepatitis C Virus Infection and Vaccine Development.

Authors:  Xuan Guo; Jin-Yi Zhong; Jun-Wen Li
Journal:  J Clin Exp Hepatol       Date:  2018-02-16

8.  Importance and Contribution of Community, Social, and Healthcare Risk Factors for Hepatitis C Infection in Pakistan.

Authors:  Adam Trickey; Margaret T May; Charlotte Davies; Huma Qureshi; Saeed Hamid; Hassan Mahmood; Quaid Saeed; Matthew Hickman; Nancy Glass; Francisco Averhoff; Peter Vickerman
Journal:  Am J Trop Med Hyg       Date:  2017-10-12       Impact factor: 2.345

Review 9.  Influence of host resistance on viral adaptation: hepatitis C virus as a case study.

Authors:  Anne Plauzolles; Michaela Lucas; Silvana Gaudieri
Journal:  Infect Drug Resist       Date:  2015-04-07       Impact factor: 4.003

Review 10.  New prospects for the treatment and prevention of hepatitis C in children.

Authors:  Samantha Ohmer; Jonathan Honegger
Journal:  Curr Opin Pediatr       Date:  2016-02       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.